News Alert

Merck Extends its Conditions on 340B Pricing Involving Contract Pharmacies to Health Centers

Merck exterior building sign
Merck extended its restrictions on 340B pricing involving contract pharmacies to community health centers.

Drug manufacturer Merck today extended its restrictions on 340B pricing involving contract pharmacies to community health centers. The restrictions have applied only to hospital covered entities until now.

Other grantee covered entities remain exempt “at this time,” Merck

Read More »

Providers Alarmed About 45-Day Lookback Clauses in Drug Makers’ 340B Contract Pharmacy Policies

closeup of sand in an hourglass
Covered entities are concerned about 45-day time limits for claims submissions and replenishment orders in drug manufacturers' 340B contract pharmacy policies.

Drug manufacturer Sanofi drew attention this month when it added 45-day time limits for replenishment orders and claims submissions to its conditions on 340B pricing when covered entities use contract pharmacies.

Pfizer and Amgen also recently added similar 45-day

Read More »

HIV/AIDS Clinics Tell FTC that PBMs Usurp 340B Discounts for Themselves

sculpture of a man and horse outside a federal building
The "Man Controlling Trade" statute outside the FTC's Washington, D.C., headquarters. HIV/AIDS clinics recently submitted comments to the commission about PBMs' business practices.

Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.

RWC-340B asked the

Read More »

Influential HIV/AIDS Group Asks Gilead to Exempt Ryan White Clinics from Company’s 340B Contract Pharmacy Restrictions

Gilead exterior office sign
Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies wholly owned by covered entities.

Ryan White Clinics for 340B Access (RWC-340B) has asked drug manufacturer Gilead to exempt all Ryan White clinics from the company’s conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

RWC-340B

Read More »

Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines

Six HIV/AIDS and viral hepatitis advocacy groups issued a joint statement criticizing AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

UPDATE Thursday, April 21, 2022, 5:00 p.m. EDT—AbbVie issued this statement: AbbVie supports the 340B program and is committed to the program’s goal of improving access to medicines for uninsured and vulnerable patients. Our 340B initiative does not block

Read More »

340B Hospitals’ Pharmacies and Child Sites Often Located in Richer, Less Diverse Areas, Study Finds

bottles of drugs on pharmacy shelves
Avalere Health says it found that 340B DSH hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations.

340B disproportionate share (DSH) hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations, according to a new study.

Healthcare consulting firm

Read More »

JAMA Study Finds Prominent Cancer Centers With 340B Connections Mark Up Infused Drugs Significantly

New research in JAMA Internal Medicine says many NCI-designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially." 340B groups point out that the rates are negotiated and they need the revenue for their safety net mission.

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine. Hospital groups have

Read More »

At Direction of U.S. Appeals Court, Judge Issues Amended Judgement in Lilly’s 340B Contract Pharmacy Case

Senior District Court Judge Sarah Evans Barker
It is unknown whether U.S. Senior District Judge Sarah Evans Barker’s amended partial final judgement in Lilly's 340B contract pharmacy lawsuit will satisfy a higher court that kicked the case back to her.

A federal district judge in Indianapolis last week responded to a higher court’s directive and entered an amended partial final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit. It is not clear whether the judge did enough to

Read More »

Sanofi Makes Two Big Changes to its 340B Contract Pharmacy Policy

Sanofi outdoor building sign
Changes to Sanofi's 340B drug pricing conditions may eliminate 340B discounts for health centers using multiple contract pharmacies within a chain.

Drug manufacturer Sanofi has made two major changes to its conditions on 340B pricing when health centers and certain hospitals and use contract pharmacies, a company spokesperson confirms. One is raising flags among 340B providers and the other appears

Read More »

Feds Tell Court Tennessee Health System Paid for Referrals to Recoup “Staggering” 340B Discounts

Methodist University Hospital building mounted sign
The federal government told a court this week that Methodist Le Bonheur Healthcare agreed to pay a private oncology practice "for referrals and the opportunity to recoup discounts through the 340B program." Methodist has vowed to vigorously defend itself against what it says are meritless claims.

The federal government on Monday accused a Tennessee health system of unlawfully paying a Memphis-area private oncology practice for patient referrals, letting the system “recoup a staggering discount in costs” through the 340B program. The 340B health system—Methodist Le

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live